Maze Therapeutics Q2 2026: cash $494.9M, net loss $44.7M; pipeline milestones on track

Maze Therapeutics, Inc.

Cash, equivalents and marketable securities $494.9M at 6/30/26 vs $360.0M at 12/31/25; runway into 2029.
Q2 2026 net loss $44.7M ($0.76/share) vs $33.7M ($0.77/share) in Q2 2025; H1 loss $68.9M ($1.22/share).
R&D expenses Q2 $34.9M (vs $28.1M); G&A $13.1M (vs $8.4M); both up on clinical progress and personnel costs.
Recognized $20M H1 2026 license revenue from Shionogi milestone for MZE001 (Pompe disease).
MZE829 HORIZON updated data late 2026/early 2027 (3 cohorts); pivotal trial H1 2027. MZE782 PKU topline 2027; CKD trial H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.